Cryosite (ASX:CTE) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jun. 30, 2026)


ASX:CTE Cryosite Ltd ASX:CTE
51 GF Score
Price A$1.25
GF Value A$0.94
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cryosite Float Percentage Of Total Shares Outstanding?

Cryosite ASX:CTE 51 Float Percentage Of Total Shares Outstanding is 0.00% as of Jun. 30, 2026. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cryosite's float shares is 0.00 Mil. Cryosite's total shares outstanding is 48.81 Mil. Cryosite's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cryosite's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cryosite's Institutional Ownership is 0.00%.

ASX:CTE
51GF Score
Cryosite Ltd ASX:CTE
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryosite Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cryosite's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/48.81
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Cryosite (ASX:CTE) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Cryosite and its competitors.
Is Cryosite's Float Percentage Of Total Shares Outstanding too high?
Cryosite's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Cryosite has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Float Percentage Of Total Shares Outstanding compare to TMO and DHR?
Cryosite's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Medical Diagnostics & Research company?
A good Float Percentage Of Total Shares Outstanding depends on the Medical Diagnostics & Research industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Cryosite and its competitors. Cryosite's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.25 — trading 33% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. Cryosite's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.25 is trading 33% above its estimated GF Value™ of A$0.94. GuruFocus considers Cryosite to be Significantly Overvalued.

Key valuation signals for ASX:CTE:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: A$0.94 vs. price of A$1.25 (33% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score

Get the complete analysis for ASX:CTE

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.25
Price
A$0.94
GF Value